Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Podell

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Vaccine|September 26, 2020
BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosisSangeeta Tiwari, Taru S Dutt, Bing Chen, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2023
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis modelMichelle E Ramey, Firat Kaya, Allison A Bauman, et al.
Vaccines|April 30, 2021
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge ModelIzabela K Ragan, Lindsay M Hartson, Taru S Dutt, et al.
Antimicrobial Agents and Chemotherapy|August 11, 2023
Lung microenvironments harbor <i>Mycobacterium tuberculosis</i> phenotypes with distinct treatment responsesNicholas D Walter, Jackie P Ernest, Christian Dide-Agossou, et al.
Npj Antimicrobials and Resistance|January 22, 2025
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniquesHazem F M Abdelaal, Bryan J Berube, Brendan K Podell, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2022
A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case StudyFirat Kaya, Jacqueline P Ernest, Katherine LoMauro, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2021
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832Gregory T Robertson, Michelle E Ramey, Lisa M Massoudi, et al.
Current HIV Research|December 25, 2019
Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID WorkshopRamesh Akkina, Daniel L Barber, Moses T Bility, et al.
Science Translational Medicine|February 23, 2022
Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in <i>Mycobacterium abscessus</i>Juan Manuel Belardinelli, Deepshikha Verma, Wei Li, et al.
Nature Communications|May 19, 2021
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimensNicholas D Walter, Sarah E M Born, Gregory T Robertson, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Vaccine|September 26, 2020
BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosisSangeeta Tiwari, Taru S Dutt, Bing Chen, et al.
Antimicrobial Agents and Chemotherapy|October 4, 2023
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis modelMichelle E Ramey, Firat Kaya, Allison A Bauman, et al.
Vaccines|April 30, 2021
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge ModelIzabela K Ragan, Lindsay M Hartson, Taru S Dutt, et al.
Antimicrobial Agents and Chemotherapy|August 11, 2023
Lung microenvironments harbor <i>Mycobacterium tuberculosis</i> phenotypes with distinct treatment responsesNicholas D Walter, Jackie P Ernest, Christian Dide-Agossou, et al.
Npj Antimicrobials and Resistance|January 22, 2025
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniquesHazem F M Abdelaal, Bryan J Berube, Brendan K Podell, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2022
A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case StudyFirat Kaya, Jacqueline P Ernest, Katherine LoMauro, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2021
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832Gregory T Robertson, Michelle E Ramey, Lisa M Massoudi, et al.
Current HIV Research|December 25, 2019
Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID WorkshopRamesh Akkina, Daniel L Barber, Moses T Bility, et al.
Science Translational Medicine|February 23, 2022
Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in <i>Mycobacterium abscessus</i>Juan Manuel Belardinelli, Deepshikha Verma, Wei Li, et al.
Nature Communications|May 19, 2021
Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimensNicholas D Walter, Sarah E M Born, Gregory T Robertson, et al.
Pageof 8